Adjunctive intra-arterial tenecteplase after successful endovascular thrombectomy in patients with large vessel occlusion stroke (POST-TNK): Study rationale and design

Huang, Jiacheng, Guo, Changwei, Yang, Jie, Shi, Xiaolei, Liu, Chang, Song, Jiaxing, Li, Fengli, Kong, Weilin, Fan, Shitao, Peng, Zhouzhou, Yang, Shihai, Ma, Jinfu, Xu, Xu, Li, Linyu, Wang, Zhixi, Yu, Nizhen, Sun, Wenzhe, Yue, Chengsong, Liu, Xiang, Yang, Dahong, Huang, Cheng, Wang, Duolao ORCID: https://orcid.org/0000-0003-2788-2464, Nogueira, Raul G, Nguyen, Thanh N, Saver, Jeffrey L, Chen, Yangmei and Zi, Wenjie (2024) 'Adjunctive intra-arterial tenecteplase after successful endovascular thrombectomy in patients with large vessel occlusion stroke (POST-TNK): Study rationale and design'. European Stroke Journal. (In Press)

Preview

Text (Reuse is restricted to non-commercial and no derivative uses) POST-TNK-ESJ.pdf - Accepted Version Download (863kB) | Preview

Abstract

Rationale: Adjunct intra-arterial alteplase has been shown to potentially improve clinical outcomes in patients with large vessel occlusion (LVO) stroke who have undergone successful endovascular thrombectomy. Tenecteplase, known for its enhanced fibrin specificity and extended activity duration, could potentially enhance outcomes in stroke patients after successful reperfusion when used as an adjunct intra-arterial therapy. Aim: To explore the safety and efficacy of intra-arterial tenecteplase after successful endovascular thrombectomy in patients with LVO stroke.
Sample size: To randomize 498 participants 1:1 to receive intra-arterial tenecteplase or no intra-arterial adjunctive thrombolysis therapy.
Methods and design: An investigator-initiated, prospective, randomized, open-label, blind-endpoint multicenter clinical trial. Eligible patients with anterior circulation LVO stroke presenting within 24 h from symptom onset (time last known well) and excellent to complete reperfusion (expanded Thrombolysis In Cerebral Infarction (eTICI) scale 2c–3) at endovascular thrombectomy are planned to be randomized.
Outcomes: The primary outcome is freedom from disability (modified Rankin Scale, mRS, of 0–1) at 90 days. The primary safety outcomes are mortality through 90 days and symptomatic intracranial hemorrhage within 48 h.
Discussion: The POST-TNK trial will evaluate the efficacy and safety of intra-arterial tenecteplase in patients with LVO stroke and excellent to complete reperfusion.

Item Type:	Article
Subjects:	QV Pharmacology > Hematologic Agents > QV 190 Drugs affecting blood coagulation WB Practice of Medicine > WB 102.5 Clinical medicine - evidence-based practice WL Nervous System > WL 300 General works (Include works on brain alone)
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1177/23969873241286983
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	06 Nov 2024 11:49
Last Modified:	06 Nov 2024 11:49
URI:	https://archive.lstmed.ac.uk/id/eprint/25449

Statistics

View details

Actions (login required)

Edit Item